http://content.healthaffairs.org/cgi/content/abstract/24/6/1571
Results of randomized clinical trials are the
preferred "evidence" for establishing the benefits and
safety of medical treatments. We present evidence suggesting that
the conventional approach to reporting clinical trials has
fundamental flaws that can result in overlooking identifiable
subgroups harmed by a treatment while underestimating benefits to
others. A risk-stratified approach can dramatically reduce the
chances of such errors. Since professional and economic incentives
reward advocating treatments for as broad a patient population as
possible, we suggest that payers and regulatory bodies might need to
act to motivate prompt, routine adoption of risk-stratified
assessments of medical treatments’ safety and benefits.
One of the more salient articles on the pros and
cons of heterogeneity and usual sub-group anlaysis, apologies if others had already
shared this with the list.
Dan Sontheimer, MD
Springfield, MO